Drugs / LOMECITINIB
LOMECITINIB
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06088264 | Oct → Dec 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05615012 | Nov 2022 → Dec 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05579574 | Oct 2022 → Jun 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05546151 | Sep 2022 → Apr 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04175925 | Nov 2019 → Jul 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05730725 | Apr 2023 → Aug 2024 | psoriasis | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOMECITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316168 ↗ |
| Known as | BMS-986322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05615012 ↗ |
| Known as | BMS-986322-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316168 ↗ |
| Known as | LOMEDEUCITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316168 ↗ |
| Modality | Small molecule | — CHEMBL5316168 ↗ |
| Route | Oral | “single and multiple oral doses of BMS-986322 in healthy subjects” NCT04175925 ↗ |